Phase 1/2 study of elraglusib (9-ING-41), a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, alone or with irinotecan, temozolomide/ irinotecan or cyclophosphamide/topotecan in pediatric patients with refractory malignancies: Interim results.